Development of biopolymeric nanoparticles for accurate diagnostics and targeted therapy for prostate cancer treatment (Q107913): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The project involves the development of R & D for the development of a safe and effective radiopharmaceutical, consisting of nanoparticles based on prostate radioisotope (combined diagnosis and therapy) of prostate cancer. Currently, this product type is not offered on the domestic market, as well as at European and US level. This is evidenced by the highly innovative nature of the solution being developed. In view of the increasing number of...) |
(Created claim: summary (P836): The subject of the project is to carry out R & D work to develop a safe and effective radiopharmaceutical, consisting of nanoparticles labelled with radioisotopes for therapies (joined diagnosis and therapy) of prostate cancer. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the increasing number...) |
||||||||||||||
| Property / summary | |||||||||||||||
The subject of the project is to carry out R & D work to develop a safe and effective radiopharmaceutical, consisting of nanoparticles labelled with radioisotopes for therapies (joined diagnosis and therapy) of prostate cancer. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the increasing number of cancers (including prostate) and the increasing ageing of the population, there is an urgent need for the results of this project, which will contribute to improving health and saving many lives. The target group of the project is the medical staff (skilled medical workers in the oncological specialisation) and the population of men with prostate cancer. The project involves carrying out two stages of industrial research and one stage of experimental development. Industrial research and development will be carried out by the Applicant (with qualified and experienced research and management staff and relevant technical resources) and by an external subcontractor selected in a competitive procedure. In addition to employed research staff, external experts will also be involved in the implementation of the project, thanks to which the project will be implemented on the basis of user-oriented design methods. In order to protect intellectual property created in the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and the efficient use of natural resources. (English) | |||||||||||||||
| Property / summary: The subject of the project is to carry out R & D work to develop a safe and effective radiopharmaceutical, consisting of nanoparticles labelled with radioisotopes for therapies (joined diagnosis and therapy) of prostate cancer. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the increasing number of cancers (including prostate) and the increasing ageing of the population, there is an urgent need for the results of this project, which will contribute to improving health and saving many lives. The target group of the project is the medical staff (skilled medical workers in the oncological specialisation) and the population of men with prostate cancer. The project involves carrying out two stages of industrial research and one stage of experimental development. Industrial research and development will be carried out by the Applicant (with qualified and experienced research and management staff and relevant technical resources) and by an external subcontractor selected in a competitive procedure. In addition to employed research staff, external experts will also be involved in the implementation of the project, thanks to which the project will be implemented on the basis of user-oriented design methods. In order to protect intellectual property created in the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and the efficient use of natural resources. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The subject of the project is to carry out R & D work to develop a safe and effective radiopharmaceutical, consisting of nanoparticles labelled with radioisotopes for therapies (joined diagnosis and therapy) of prostate cancer. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the increasing number of cancers (including prostate) and the increasing ageing of the population, there is an urgent need for the results of this project, which will contribute to improving health and saving many lives. The target group of the project is the medical staff (skilled medical workers in the oncological specialisation) and the population of men with prostate cancer. The project involves carrying out two stages of industrial research and one stage of experimental development. Industrial research and development will be carried out by the Applicant (with qualified and experienced research and management staff and relevant technical resources) and by an external subcontractor selected in a competitive procedure. In addition to employed research staff, external experts will also be involved in the implementation of the project, thanks to which the project will be implemented on the basis of user-oriented design methods. In order to protect intellectual property created in the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and the efficient use of natural resources. (English) / qualifier | |||||||||||||||
point in time: 17 October 2020
| |||||||||||||||
Revision as of 17:15, 17 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of biopolymeric nanoparticles for accurate diagnostics and targeted therapy for prostate cancer treatment |
Project in Poland financed by DG Regio |
Statements
1,714,809.61 zloty
0 references
2,271,840.81 zloty
0 references
75.48 percent
0 references
7 June 2016
0 references
30 June 2019
0 references
NANOTHEA SPÓŁKA AKCYJNA
0 references
52°14'1.3"N, 21°4'17.0"E
0 references
Przedmiotem projektu jest przeprowadzenie prac B+R, w celu opracowania bezpiecznego i skutecznego radiofarmaceutyku, składającego się z nanocząstek wyznakowanych radioizotopami do teranostyki (połączonej diagnostyki i terapii) nowotworu prostaty. Obecnie, tego typu produkt nie jest oferowany na rynku krajowym, a także europejskim i w USA. Powyższe świadczy o wysokiej innowacyjności opracowywanego rozwiązania. W związku z rosnącą liczbą zachorowań na nowotwory (w tym prostaty) i nasilającym się zjawiskiem starzenia się społeczeństwa, odnotowywane jest pilne zapotrzebowania na rezultaty niniejszego projektu, które przyczynią się do poprawy zdrowia i uratowania wielu ludzkich istnień. Grupę docelową projektu stanowi personel medyczny (wykwalifikowani pracownicy medyczni w specjalizacji onkologicznej) oraz populacja mężczyzn, u której występuje nowotwór prostaty. Projekt obejmuje przeprowadzenie dwóch etapów badań przemysłowych i jednego etapu eksperymentalnych prac rozwojowych. Badania przemysłowe i prace rozwojowe realizowane będą przez Wnioskodawcę (dysponującego wykwalifikowaną i doświadczoną kadrą badawczą i zarządzającą oraz odpowiednimi zasobami technicznymi) oraz przez wyłonionego w procedurze konkurencyjnej zewnętrznego podwykonawcę. W realizację projektu, oprócz zatrudnionych pracowników badawczych, zaangażowani zostaną również zewnętrzni eksperci, dzięki czemu projekt realizowany będzie w oparciu o metody projektowania zorientowanego na użytkownika. W celu ochrony własności intelektualnej powstałej w projekcie, planowane jest dokonanie zgłoszenia patentowego. Projekt realizowany będzie zgodnie z zasadami oszczędności energii i efektywnego wykorzystania zasobów naturalnych. (Polish)
0 references
The subject of the project is to carry out R & D work to develop a safe and effective radiopharmaceutical, consisting of nanoparticles labelled with radioisotopes for therapies (joined diagnosis and therapy) of prostate cancer. Currently, this type of product is not offered on the domestic market as well as on the European market and in the USA. This demonstrates the high innovativeness of the developed solution. In view of the increasing number of cancers (including prostate) and the increasing ageing of the population, there is an urgent need for the results of this project, which will contribute to improving health and saving many lives. The target group of the project is the medical staff (skilled medical workers in the oncological specialisation) and the population of men with prostate cancer. The project involves carrying out two stages of industrial research and one stage of experimental development. Industrial research and development will be carried out by the Applicant (with qualified and experienced research and management staff and relevant technical resources) and by an external subcontractor selected in a competitive procedure. In addition to employed research staff, external experts will also be involved in the implementation of the project, thanks to which the project will be implemented on the basis of user-oriented design methods. In order to protect intellectual property created in the project, a patent application is planned. The project will be implemented in accordance with the principles of energy saving and the efficient use of natural resources. (English)
17 October 2020
0 references
Identifiers
RPMA.01.02.00-14-5723/16
0 references